Catalyst Pharmaceutical Partners (CPRX)

[DonShimoda]

Ocular Safety Pilot Results (pdf)

Key Findings:

The long-term use of vigabatrin for the treatment of patients with epilepsy has been associated with
the development of visual field defects.

The short-term use of vigabatrin seems promising for treating cocaine and methamphetamine abuse. No visual field defects developed with short-term use in this pilot study.

No changes in acuity and no ocular adverse effects were
encountered.

http://www.catalystpharma.com/pdf/OcularSafety.pdf